110 results about "Membrane antigen" patented technology

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.

The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.

Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.

Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.

The invention belongs to the fields of immunology and cell biology, and relates to a tumor precision T cell containing an efficient killing starting mechanism and an application of the tumor precision T cell, in particular to a CAR (chimeric antigen receptor) having moderate-affinity binding characteristic with a broad-spectrum expression membrane antigen on the tumor cell surface as well as a new-generation tumor precision T cell, namely, Baize T. T cell activation is started rapidly under the action of the CAR having the moderate-affinity binding characteristic, an activation signal of the CAR is superposed with a TCR (T cell receptor) signal with tumor antigen natural recognition capacity in a CTL (tumor-specific cytotoxic T lymphocyte), the CTL is activated to proliferate and grow in a tumor microenvironment, and a tumor cell is killed preciously by the tumor-antigen-specific TCR. The tumor precision T cell has broad anti-tumor application prospect.

Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.

The invention provides a method for preserving the activity of a human cell membrane blood group antigen, which comprises the steps of: preparing an erythrocyte membrane blood group antigen extract, and then coating the prepared erythrocyte membrane blood group antigen on a solid microsphere so as to replace a fresh erythrocyte to be used for detecting a blood group antibody in a sample.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

The invention discloses a preparation method of an autologous platelet-factor-rich plasma (PFRP) preparation. The preparation method is characterized by comprising the steps of: A, preparation of autologous PFRP, to be specific, collecting autologous whole blood, and preparing the autologous PFRP in a centrifuging and freeze-thawing manner; and B, preparation of the PFRP preparation, to be specific, mixing the obtained PFRP with a biological scaffold / autologous somatic cells according to a volume ratio of (3:1)-(1:1) to obtain the PFRP preparation. By means of specially processing the autologous whole blood to obtain the autologous PFRP, pollution risks caused by adding an activating agent are reduced, and the immune risks of a membrane antigen during heterogenous usage are avoided. The autologous PFRP preparation prepared according to the method not only has a good effect of repairing damaged tissues such as meniscus, but also has very good anti-wrinkle, filling and lifting effects.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors

The invention discloses a DNA sequence expressing a truncated treponema pallidum membrane antigen and an amino acid sequence The membrane antigen is removed of the part having high homology with human fibronectin, so as to avoid false positive and improve the specificity of the serological test for diagnosis of treponema pallidum infection. The invention also discloses the application of the membrane antigen in preparing diagnostic reagents for detecting treponema pallidum infection.

The invention discloses a method for separating sperm in a sperm and epithelial cell mixed stain by using immunological magnetic beads, which comprises the following steps: 1) labeling an anti-sperm membrane protein antibody with biotin; 2) combining sperm and the antibody; 3) combining magnetic beads and the antibody-sperm complex; 4) separating the sperm and an epithelial cell; and 5) separating the sperm and the magnetic beads. According to the method, the anti-sperm membrane protein antibody is labeled with the biotin, and coupling to the biotin is realized through avidin (coated on the magnetic beads), thus successfully constructing the magnetic bead-avidin-biotin-antibody-membrane antigen (sperm) complex; and a related reagent system is optimized, and a corresponding operation procedure is established, thus improving energy efficiency of mixed stain examination. The method has the advantages of fewer procedures, simple operation, convenient popularization and the like, and can provide theoretical and practical foundations for automatic examination.

A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt. Definitions of R1-R13 and L1-L4 are provided in the disclosure, and R14 is a group capable of binding to prostate-specific membrane antigen (PSMA).

Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by Chlamydia infection. The immunogenic compositions may comprise the major outer membrane protein (MOMP) of Chlamydia which may be in a homooligomeric form or complexed with at least one other antigen of Chlamydia. The immunogenic composition may include an immunostimulating complex (ISCOM) and the outer membrane antigen may be incorporated therein. The immunogenic compositions have utility as chlamydial vaccines and in diagnostic applications.

The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1 / MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.

The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through a reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an EGFRvIII monoclonal antibody, conferring specific immunity against EGFRvIII positive cells. The TCR KO engineered immune cells endowed with such CARs are particularly suited for treating lung cancer, anal cancers and glioblastoma multiforme.

The invention provides a prostate-specific antigen targeting inhibitor of a nuclide marker. The targeting inhibitor is DKFZ-PSMA-617 of a radioactive nuclide marker. Radioactive nuclide includes at least one of 64Cu, 68Ga and 89Zr. The invention further provides a preparation method of the nuclide marker DKFZ-PSMA-617. The nuclide marker DKFZ-PSMA-617 is stable in property and good in development effect, has high affinity and functional activity on PSMA, is beneficial to diagnosis and accurate staging of early prostate cancer, and provides a new thought for diagnosis of breast cancer and gastric adenocarcinoma. Further preclinical animal level research proves that the inhibitor is expected to become a targeting PSMA developing agent and a tumor treatment agent with good application prospects.

The invention discloses an ELISA kit for a hepatitis C virus envelope antigen and a detection method thereof. The ELISA kit comprises an ELISA plate, three polypeptides (12-peptide ZA, 12-peptide ZB and 12-peptide ZD) which are labeled by biotin and capable of being in specific binding with HCV E2 protein, a rabbit anti-E2 polyclonal antibody and streptavidin labeled by horseradish peroxidase. A method of the kit for detecting the hepatitis C virus envelope antigen comprises the following steps: firstly, coating the rabbit anti-E2 polyclonal antibody; then adding blood serum of a patient to be detected; thirdly, adding the polypeptides labeled by the biotin; fourth, adding the streptavidin labeled by the horseradish peroxidase; and fifth, adding o-phenylenediamine for color development and reading an OD value by an ELISA reader at OD450nm. The polypeptides and labels thereof are applied to the kit for detecting the hepatitis C virus envelope antigen. Meanwhile, the polypeptides can also be used for preparing a medicine for treating or preventing the hepatitis C virus infection. The ELISA kit can be widely used in medicine-related fields and the like.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

The present invention provides, inter alia, isolated monoclonal and polyclonal anti-tumor endothelial marker 8 (TEM8) antibodies or antigen binding fragments thereof that (a) bind to TEM8 membrane antigen in its native form occurring on the surface of a tumor cell; (b) may be internalized by a tumor cell; (c) bind strongly to tumor cells but not or only minimally to cells which lack expression of TEM8; and (d) are characterized in that the mean fluorescence intensity (MFI) of the antibody or an antigen binding fragment thereof against a mammalian cell line expressing TEM8 is at least two times higher than the MFI against the mammalian cell line not expressing TEM8 at antigen saturation. Chimeric antigen receptors (CARs) including an antigen binding fragment of such antibodies, modified antibodies, compositions, pharmaceutical compositions, and kits including the antibodies according to the present invention, and methods of use are also provided.

The invention belongs to the technical field of biomedicines and in particular relates to a PSMA (Prostate-Specific Membrane Antigen) inhibitor, a compound and application. The PSMA inhibitor of a novel core structure, which is provided by the invention, has very high affinity, is stable in structure and has wide application prospects.

Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by Chlamydia infection The immunogenic compositions may comprise the major outer membrane protein (MOMP) of Chlamydia which may be in a homooligomeric form or complexed with at least one other antigen of Chlamydia. The immunogenic composition may include an immunostimulating complex (ISCOM) and the outer membrane antigen may be incorporated therein. The immunogenic compositions have utility as chlamydial vaccines and in diagnostic applications.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.